Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus infection as an opportunistic disease in persons
infected with human immunodeficiency virus. Clin Infect Dis.2000;30(suppl 1):S77-S84.
Broers B, Junet C, Bourquin M.
et al. Prevalence and incidence rate of HIV, hepatitis B and C among drug
users on methadone maintenance treatment in Geneva between 1988 and 1995. AIDS.1998;12:2059-2066.
Darby SC, Ewart DW, Giangrande PL.
et al. Mortality from liver cancer and liver disease in haemophilic men and
boys in UK given blood products contaminated with hepatitis C. Lancet.1997;350:1425-1431.
Monga HK, Rodriguez-Barradas MC, Breaux K.
et al. Hepatitis C virus infection-related morbidity and mortality among patients
with human immunodeficiency virus infection. Clin Infect Dis.2001;33:240-247.
Lesens O, Deschenes M, Steben M.
et al. Hepatitis C virus is related to progressive liver disease in human
immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic
infection. J Infect Dis.1999;179:1254-1258.
Eyster ME, Diamondstone LS, Lien JM.
et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs. J Acquir Immune Defic Syndr.1993;6:602-610.
Sherman KE, O'Brien J, Gutierrez G.
et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent
human immunodeficiency virus infections. J Clin Microbiol.1993;31:2679-2682.
Thomas DL, Astemborski J, Rai RM.
et al. The natural history of hepatitis C virus infection. JAMA.2000;284:450-456.
Thomas DL, Astemborski J, Vlahov D.
et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis.2000;181:844-851.
Sabin CA, Telfer P, Phillips AN.
et al. The association between hepatitis C virus genotype and human immunodeficiency
virus disease progression in a cohort of hemophilic men. J Infect Dis.1997;175:164-168.
Piroth L, Duong M, Quantin C.
et al. Does hepatitis C virus co-infection accelerate clinical and immunological
evolution of HIV-infected patients? AIDS.1998;12:381-388.
Quan S, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency
virus. Clin Infect Dis.1993;17:117-119.
Wright TL, Hollander H, Pu X.
et al. Hepatitis C in HIV-infected patients with and without AIDS. Hepatology.1994;20:1152-1155.
Staples Jr CT, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A.
(Veterans Affairs Medical Center) Cohort Study (HAVACS). Clin Infect Dis.1999;29:150-154.
Dorrucci M, Pezzotti P, Phillips AN.
et al. Coinfection of hepatitis C virus with human immunodeficiency virus
and progression to AIDS. J Infect Dis.1995;172:1503-1508.
Macias J, Pineda JA, Leal M.
et al. Influence of hepatitis C virus infection on the mortality of antiretroviral-treated
patients with HIV disease. Eur J Clin Microbiol Infect Dis.1998;17:167-170.
Haydon GH, Flegg PJ, Blair CS.
et al. The impact of chronic hepatitis C virus infection on HIV disease and
progression in intravenous drug users. Eur J Gastroenterol Hepatol.1998;10:485-489.
Greub G, Ledergerber B, Battegay M.
et al. Clinical progression, survival, and immune recovery during antiretroviral
therapy in patients with HIV-1 and hepatitis C virus coinfection. Lancet.2000;356:1800-1805.
Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an
urban community. N Engl J Med.1994;330:763-768.
1993 revised classification system for HIV infection and expanded surveillance
case definition for AIDS among adolescents and adults. MMWR Recomm Rep.1992;41(RR-17):1-19.
Thio CL, Nolt KR, Astemborski J.
et al. Screening for hepatitis C virus in human immunodeficiency virus-infected
individuals. J Clin Microbiol.2000;38:575-577.
National Institutes of Health Consensus Development Conference Panel
statement: management of hepatitis C. Hepatology.1997;26(suppl 1):2S-10S.
Manns MP, McHutchison JG, Gordon SC.
et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b
plus ribavirin for initial treatment of chronic hepatitis C. Lancet.2001;358:958-965.
Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in
cohort studies of common outcomes. JAMA.1998;280:1690-1691.
Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected
with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA.2000;283:74-80.
den Brinker M, Wit FW, Wertheim-van Dillen PM.
et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity
of highly active antiretroviral therapy in HIV-1 infection. AIDS.2000;14:2895-2902.
Martinez E, Blanco JL, Arnaiz JA.
et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing
antiretroviral therapy. AIDS.2001;15:1261-1268.
Escaffre N, Morin M, Bouhnik AD.
et al. Injecting drug users' adherence to HIV antiretroviral treatments. AIDS Care.2000;12:723-730.
Celentano DD, Vlahov D, Cohn S.
et al. Self-reported antiretroviral therapy in injection drug users. JAMA.1998;280:544-546.
Strathdee SA, Palepu A, Cornelisse PG.
et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA.1998;280:547-549.
Mocroft A, Madge S, Johnson AM.
et al. A comparison of exposure groups in the EuroSIDA study. J Acquir Immune Defic Syndr.1999;22:369-378.
Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment
of HIV-1 infection. J Acquir Immune Defic Syndr.2001;27:251-259.
Detels R, Munoz A, McFarlane G.
et al. Effectiveness of potent antiretroviral therapy on time to AIDS and
death in men with known HIV infection duration. JAMA.1998;280:1497-1503.
Hogg RS, Heath KV, Yip B.
et al. Improved survival among HIV-infected individuals following initiation
of antiretroviral therapy. JAMA.1998;279:450-454.
Palella Jr FJ, Delaney KM, Moorman AC.
et al. Declining morbidity and mortality among patients with advanced human
immunodeficiency infection. N Engl J Med.1998;338:853-860.
Hughes MD, Stein DS, Gundacker HM.
et al. Within-subject variation in CD4 lymphocyte count in asymptomatic human
immunodeficiency virus infection. J Infect Dis.1994;169:28-36.
Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death
statement. Arch Intern Med.2001;161:277-284.
Goedert JJ, Fung MW, Felton S.
et al. Cause-specific mortality associated with HIV and HTLV-II infections
among injecting drug users in the USA. AIDS.2001;15:1295-1302.
Prins M, Hernandez Aguado IH, Brettle RP.
et al. Pre-AIDS mortality from natural causes associated with HIV disease
Alter MJ, Kruszon-Moran D, Nainan OV.
et al. The prevalence of hepatitis C virus infection in the United States,
1988 through 1994. N Engl J Med.1999;341:556-562.
Lok AS, Gunaratnam NT. Diagnosis of hepatitis C. Hepatology.1997;26(suppl 1):48S-56S.
Tillmann HL, Heiken H, Knapik-Botor A.
et al. Infection with GB virus C and reduced mortality among HIV-infected
patients. N Engl J Med.2001;345:715-724.
Xiang J, Wunschmann S, Diekema DJ.
et al. Effect of coinfection with GB virus C on survival among patients with
HIV infection. N Engl J Med.2001;345:707-714.
Thomas DL, Vlahov D, Alter HJ.
et al. The association of antibody to GB virus C (hepatitis G virus) with
viral clearance and protection from reinfection. J Infect Dis.1998;177:539-542.
Yeo AE, Matsumoto A, Hisada M.
et al. Effect of hepatitis G virus infection on progression of HIV infection
in patients with hemophilia. Ann Intern Med.2000;132:959-963.
Christensen JK, Eugen-Olsen J, Sorensen M.
et al. Prevalence and prognostic significance of infection with TT virus in
patients infected with human immunodeficiency virus. J Infect Dis.2000;181:1796-1799.